Andreas Halvorsen's WST Position Overview
Andreas Halvorsen (via Viking Global Investors Lp) currently holds 416,948 shares of West Pharmaceutical Services, Inc. (WST) worth $104.5 M, representing 0.29% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 2 quarters.
Based on recent 13F filings, Andreas Halvorsen has initiated a new position in WST, representing a fresh investment thesis on this company. Largest addition occurred in Q1 2026, adding 121,920 shares.
Analysis based on 13F filings available since 2013 Q2
Andreas Halvorsen's West Pharmaceutical Services (WST) Holding Value Over Time
Track share changes against reported price movement
Quarterly West Pharmaceutical Services (WST) Trades by Andreas Halvorsen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +121,920 | Add 41.32% | 416,948 | $250.64 |
| Q4 2025 | +295,028 | New Buy | 295,028 | $275.14 |
Andreas Halvorsen's West Pharmaceutical Services Investment FAQs
Andreas Halvorsen first purchased West Pharmaceutical Services, Inc. (WST) in Q4 2025, acquiring 295,028 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Andreas Halvorsen has held West Pharmaceutical Services, Inc. (WST) for 2 quarters since Q4 2025.
Andreas Halvorsen's largest addition to West Pharmaceutical Services, Inc. (WST) was in Q4 2025, adding 295,028 shares worth $81.17 M.
According to the latest 13F filing for Q1 2026, Andreas Halvorsen's firm, Viking Global Investors Lp, owns 416,948 shares of West Pharmaceutical Services, Inc. (WST), valued at approximately $104.5 M.
As of the Q1 2026 filing, West Pharmaceutical Services, Inc. (WST) represents approximately 0.29% of Andreas Halvorsen's publicly disclosed stock portfolio, making it one of their key holdings.
Andreas Halvorsen's peak holding in West Pharmaceutical Services, Inc. (WST) was 416,948 shares, as reported at the end of Q1 2026.